Japan is considering a new approach to its “special” market expansion re-pricing that would exclude drug sales tied to private…
HOME > ARCHIVE
ARCHIVE
- Pfizer Files Simultaneous Application for Crizotinib in the US, Japan
June 6, 2011
- Kyorin HD: Double-Digit Growth in Sales, Profits Driven by Kipres
June 6, 2011
- Chugai Applies for Pediatric Use, Dosage of CellCept
June 6, 2011
- Kaken: Operating Profits Up 20%
June 6, 2011
- BM Files for Breast Cancer for Paraplatin Based on Public Knowledge
June 6, 2011
- Mochida: Net Profits Down 46% due to Earthquake
June 6, 2011
- Korosho Designates Velaglucerase Alfa as Orphan Drug for Gaucher's Disease
June 6, 2011
- Kissei: Sales Up 3.6% Driven by Major Products Including Urief
June 6, 2011
- 17 Companies to List Actos Generics in June, 9 to Delay Listing
June 6, 2011
- Nippon Shinyaku: Sales Up 0.9% to ¥63.5 Bil. Driven by Cialis, Lunabell
June 6, 2011
- Some GE Houses to Delay Listing Actos Generics for 1 Year
June 6, 2011
- Sales Up 33.1% Driven by CMO Business: CMIC
June 6, 2011
- Sawai to Launch Actos Generics with Full Indications in June
June 6, 2011
- Cervarix Ranked No. 1 in GP Market in March: RepTrack Survey
June 6, 2011
- Towa Ready to Launch Generic Actos with Full Indications
June 6, 2011
- Daiichi Sankyo, AZ to Copromote Denosumab in Japan
June 6, 2011
- Toyota Tsusho to Represent GHL in Japan for Biosimilars Contract Manufacturing Service
June 6, 2011
- Wholesalers Were the Only Losers: Chairman Matsutani of Toho
June 6, 2011
- Eisai, UCL to Collaborate in Neurodegenerative Disease
June 6, 2011
- ASKA Licenses Ulipristal from Laboratoire HRA
June 6, 2011
ページ
Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…